Daring to be Different and Advancing Products Women Want

Daring to be Different and Advancing Products Women Want

We are committed to identifying, licensing or acquiring and developing candidates that expand options, improve outcomes and facilitate convenience for women. In addition to our lead products in development, our accelerator boasts a broad portfolio of diverse product candidates with first-in-category potential for women requiring or desiring new therapies in contraception, vaginal health, sexual health and fertility.


Phase 1

Phase 2

Phase 3



Bacterial Vaginosis
Collaborator: Organon

FDA Approval of XACIATO™ (clindamycin phosphate vaginal gel, 2%) on December 7, 2021

XACIATO™ (clindamycin phosphate vaginal gel, 2%)


Hormone-Free, Monthly Contraception
Collaborators: Bayer & NIH

Pivotal Phase 3 Study Expected to Commence 2022

A novel, hormone-free monthly intravaginal contraceptive candidate (Self-administered intravaginal drug/device)


Investigational hormone-free monthly intravaginal contraceptive designed to be an easy-to-use monthly option with effectiveness approaching hormonal methods; commercial partnership agreement with Bayer. There are currently no FDA-approved monthly hormone-free contraceptives. Learn More.

Sildenafil Cream, 3.6%

Female Sexual Arousal Disorder

Phase 2b Study Commenced 1Q2021

Potential first-in-category for treatment of Female Sexual Arousal Disorder (Topical cream, same active ingredient as Viagra®)

Investigational cream formulation of sildenafil, the active ingredient in Viagra®, for topical administration to treat FSAD. FSAD is a physiological condition characterized by the inability to attain or maintain sufficient genital arousal during sexual activity, for which there are no FDA-approved treatments. Of the various types of female sexual dysfunction disorders, FSAD is most analogous to erectile dysfunction in men. Learn More.


Hormone Therapy

Phase 1/2 Study Ongoing

First-in-category Sustained-Release Hormone Therapy

First-in-category combination hormone delivery for treatment of vasomotor and vaginal symptoms of menopause. Intravaginal ring (IVR) designed to release bio-identical estradiol and bio-identical progesterone over 28 days. Learn More.


Vulvar and Vaginal Atrophy

Phase 1/2 Study Ongoing

First-in-category Treatment for VVA for ER/PR+ Breast Cancer Patients

First-in-category hormone-free vaginal treatment for vulvar and vaginal atrophy (VVA) in a hormone-receptor positive, breast cancer patient population. Proprietary formulation of tamoxifen for vaginal administration. Learn More.


Pregnancy Maintenance

Phase 1 Preparation

First-in-category Sustained Release Progesterone for Pregnancy Maintenance

First-in-category progesterone delivery for pregnancy maintenance including the prevention of preterm birth and for luteal phase support as part of an IVF regimen. IVR designed to release bio-identical progesterone over 14 days.


Long-Acting, Reversible Personal Contraceptive System


First-in-category, User-Controlled, Long-Acting, Reversible Contraceptive (UC-LARC)

Levonorgestrel-releasing long-acting contraceptive implant that a woman can turn on and off herself, according to her own needs. Learn More.

ADARE 204/214^

6 & 12 Month Injectable Contraception


First-in-category 6 & 12 Month Injectable Contraception

Novel 6 & 12-month injectable formulations of etonogestrel being developed as a longer-acting, reversible method of contraception with a more predictable return to fertility.


Male or Female Contraceptive Target


First-in-category Male or Female Contraceptive Target

A potential new rapidly reversible, non-hormonal contraceptive solution with application for women and men.

^505(b)(2) regulatory pathway anticipated. *Ovaprene Post Coital Test (PCT) is a pre-pivotal clinical study.

‡DARE-HRT1 and DARE-VVA1 Phase 1 studies conducted in Australia by Daré subsidiary.

*This timeline reflects management’s estimates in the most recently filed corporate presentation and constitutes a forward-looking statement subject to qualifications under the Terms and Services of this website, including Section 13.4, Forward-Looking Statements; Disclaimer. Actual development timeline may be substantially longer, and Daré is under no obligation to update or review this estimate. “First-in-category” designation is a forward-looking statement based on management’s current expectations and currently available FDA-approved therapies.